FTSE 100 Rallies Most in 14 Months, Paced by GlaxoSmithKline, Lloyds TSB

(Bloomberg) -- U.K. stocks rose for the first time
in six days as profit reports from Lloyds TSB Group Plc and
SABMiller Plc reassured investors that earnings growth will be
sustained. The FTSE 100 Index rallied the most in 14 months.

GlaxoSmithKline Plc advanced after a panel of U.S. doctors
voted to keep the company's diabetes pill Avandia on the market.
Alliance & Leicester Plc rallied on takeover speculation.


Read more at Bloomberg Stocks News

European, Asian Stocks Rise on Speculation Credit Worries Were Overdone

(Bloomberg) -- European stocks rebounded from a
five-day slide, while Asian shares climbed for a second day as
investors speculated declines have left global equities cheap
relative to prospects for earnings growth.

Aviva Plc, HSBC Holdings Plc and UBS AG led gains by
financial stocks in Europe. GlaxoSmithKline Plc, the region's
second-largest drugmaker, jumped after a panel of medical
specialists said its Avandia drug should remain on the U.S.
market. Olympus Corp. and Hang Seng Bank Ltd. paced gains in Asia
after the companies reported higher earnings.


Read more at Bloomberg Stocks News

European Stocks Rise, Paced by Aviva, UBS, GlaxoSmithKline, BHP Billiton

(Bloomberg) -- European stocks advanced for the
first time in six days on speculation shares have become cheap
relative to prospects for earnings growth.

Aviva Plc, HSBC Holdings Plc and UBS AG led financial stocks
higher. GlaxoSmithKline Plc, the region's second-largest
drugmaker, rose after a panel of medical specialists said its
Avandia drug should remain on the U.S. market. BHP Billiton Ltd.
and Rio Tinto Group gained on higher copper prices.


Read more at Bloomberg Stocks News

Congress to press FDA over drug safety woes

(Reuters) - Lawmakers will examine this week how the FDA and manufacturer GlaxoSmithKline Plc handled data that suggested the pill Avandia might raise the chances of having a heart attack.




The controversy comes as Congress considers legislation meant to bolster the FDA's oversight of drug side effects. Some critics are using the Avandia case to try to build support for tougher safeguards.


Read more at Reuters.com Government Filings News